AVP and type 2 diabetes mellitus: The robust findings that copeptin impairs DKD prognosis both in type 1 and type 2 diabetes supports the pathogenetic role of vasopressin through the activation of a V2-receptor and perpetuates the implementation of novel promising drugs for these high-risk patients [91].